Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
Phase 4
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- Registration Number
- NCT00437255
- Lead Sponsor
- Galderma R&D
- Brief Summary
Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
- Detailed Description
Same as above.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 122
Inclusion Criteria
- Moderate to severe psoriasis involving 3-20% of the body surface area
Exclusion Criteria
- Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
- Subjects having psoriasis that involves the scalp, face, or groin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Clobetasol Propionate, 0.05% Clobex® Spray 2 Calcipotriene and betamethasone dipropionate ointment Taclonex® Ointment
- Primary Outcome Measures
Name Time Method Overall Disease Severity End of treatment (Week 4) Tolerability assessments, incidence of adverse events Baseline, Weeks 1, 2, 4 and 8
- Secondary Outcome Measures
Name Time Method Overall Disease Severity Weeks 1, 2 and 8 Investigator Global Assessment End of treatment (week 4) and Weeks 1, 2 and 8
Trial Locations
- Locations (4)
Minnesota Clinical Study Center
🇺🇸Fridley, Minnesota, United States
DermResearch, Inc.
🇺🇸Austin, Texas, United States
J & S Studies, Inc.
🇺🇸Bryan, Texas, United States
Baylor Research Institute
🇺🇸Dallas, Texas, United States
Minnesota Clinical Study Center🇺🇸Fridley, Minnesota, United States